Dimethyl fumarate for multiple sclerosis.

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Parenteral administration and partial efficacy limit current multiple sclerosis (MS) disease-modifying drugs (DMDs).
• A need exists for novel oral MS therapies with improved efficacy and safety profiles.
• BG00012 (BG-12), a fumaric acid ester (FAE), represents an emerging oral treatment option.

Purpose of the Study:

• To review the potential of BG-12 in treating MS.
• To summarize findings from experimental and clinical studies involving FAEs in MS.

Main Methods:

• Review of experimental studies on FAEs in MS models.
• Analysis of current clinical trial data for FAEs in MS patients.

Main Results:

• FAE (BG-12) demonstrates immunomodulatory and neuroprotective effects.
• Positive outcomes observed in animal models of MS.
• Phase IIb clinical trial indicates short-term efficacy and a favorable safety profile for BG-12.

Conclusions:

• BG-12 is a promising oral treatment for relapsing-remitting MS, offering anti-inflammatory and potential neuroprotective benefits.
• Oral administration enhances patient convenience compared to existing parenteral DMDs.
• Further Phase III studies are necessary to confirm BG-12's long-term role in MS management.